NCT07128628View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

423

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Dry Eye Disease
Interventions
DRUG

Lifitegrast/Perfluorohexyloctane Fixed Dose Combination

Topical ocular drop of lifitegrast and perfluorohexyloctane administered for 4 weeks

DRUG

Lifitegrast

Topical ocular drop of lifitegrast administered for 4 weeks

DRUG

Perfluorohexyloctane

Topical ocular drop of perfluorohexyloctane administered for 4 weeks

DRUG

Vehicle

Topical ocular drop with no active ingredients administered for 4 weeks

DRUG

Vehicle

Topical ocular drop with no active ingredients administered for 4 weeks

DRUG

Vehicle

Topical ocular drop with no active ingredients administered for 4 weeks

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT07128628 - A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease | Biotech Hunter | Biotech Hunter